Review on natriuretic peptides: where we are, where we are going

Bibliography

• Tresch DD. Clinical manifestations, diagnostic assessment, and etiology of heart failure in elderly patients. Clin Geriatr Med 2000;16:445-56
   PubMed Web of Science ®Google Scholar
• Stevenson LW. The limited availability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884-8
   PubMed Web of Science ®Google Scholar
• Deveraux RB, Liebson PR, Horan MJ. Recommendations concerning use of echocardiography in hypertension and general population research. Hypertension 1987;9:97-104
   Web of Science ®Google Scholar
• Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996;312:222
   PubMed Web of Science ®Google Scholar
• Wuerz RC, Meador SA. Effects of pre hospital medications on mortality and length of stay in CHF. Ann Emerg Med 1992;21(6):669-74
   PubMed Web of Science ®Google Scholar
• Rich M. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997;45:968-74
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Wang Y, Parent EM, et al. Quality of care for elderly patients hospitalized with heart failure. Arch Intern Med 1997;157(19):2242-47
   PubMed Web of Science ®Google Scholar
• McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002;39:60-9
   PubMed Web of Science ®Google Scholar
• American Heart Association. 2000 Heart and Stroke Statistical Update. Dallas, TX: american Heart Association Web site, 2000. Available from: http://americanheart.org/statistics/07other.html
   Google Scholar
• National Heart, Lung, and Blood Institute. Congestive heart failure in the United States: a new epidemic. National Heart, Lung, and Blood Institute Data Fact Sheet, 1996. Available from: http://www.nhlbi.nih.gov/health/public/heart/other/chf_abs.htm
   Google Scholar
• O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994;13:S107-12
   PubMed Web of Science ®Google Scholar
• Klinge R, Hystad M, Kjekshus J, et al. An experimental study of cardiac natriuretic peptides as markers of development of congestive heart failure. Scand J Clin Lab Invest 1998;58:683-91
   PubMed Web of Science ®Google Scholar
• Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684-9
   PubMed Web of Science ®Google Scholar
• Stingo AJ, Clavell AL, Heublein DM, et al. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol 1992;263:H1318-21
   PubMed Web of Science ®Google Scholar
• Nakao K, Ogawa Y, Suga S, et al. Molecular biology and biochemistry of the natriuretic peptide system. II. Natriuretic peptide receptors. J Hypertens 1992;10:1111-4
   PubMed Web of Science ®Google Scholar
• Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464-9
   PubMed Web of Science ®Google Scholar
• Chen HH, Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1998;32(Suppl 3):S22-8
   PubMed Web of Science ®Google Scholar
• Soeki T, Kishimoto I, Okumura H, et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 2005;45:608-16
   PubMed Web of Science ®Google Scholar
• Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88
   PubMed Web of Science ®Google Scholar
• Yan W, Sheng N, Seto M, et al. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J Biol Chem 1999;274:14926-35
   PubMed Web of Science ®Google Scholar
• Hooper JD, Scarman AL, Clarke BE, et al. Localization of the mosaic transmembrane serine protease corin to heart myocytes. Eur J Biochem 2000;267:6931-7
   PubMedGoogle Scholar
• Shimizu H, Masuta K, Aono K, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002;316:129-35
   PubMed Web of Science ®Google Scholar
• Shimizu H, Masuta K, Asada H, et al. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233-9
   PubMed Web of Science ®Google Scholar
• Crimmins DL. Human N-terminal proBNP is a monomer. Clin Chem 2005;51:1035-8
   PubMed Web of Science ®Google Scholar
• Seidler T, Pemberton C, Yandle T, et al. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Biochem Biophys Res Commun 1999;255:495-501
   PubMed Web of Science ®Google Scholar
• Hammerer-Lercher A, Halfinger B, Sarg B, et al. Analysis of Circulating Forms of proBNP and NT-proBNP in Patients with Severe Heart Failure. Clin Chem 2008;54:858-65
   PubMed Web of Science ®Google Scholar
• Yandle TG, Richards AM, Gilbert A, et al. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993;76:832-8
   PubMed Web of Science ®Google Scholar
• Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8
   PubMed Web of Science ®Google Scholar
• Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest 1995;96:1280-7
   PubMed Web of Science ®Google Scholar
• Davidson NC, Struthers AD. Brain natriuretic peptide. J Hypertens 1994;12:329-36
   PubMed Web of Science ®Google Scholar
• Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32
   PubMed Web of Science ®Google Scholar
• Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003;24:341-56
   PubMed Web of Science ®Google Scholar
• McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 2003;4(Suppl 4):S13-9
   PubMedGoogle Scholar
• Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005;123:439-45
   PubMed Web of Science ®Google Scholar
• Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85
   PubMed Web of Science ®Google Scholar
• Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54
   PubMed Web of Science ®Google Scholar
• Moe GW, Howlett J, Januzzi JL, et al. N-terminal pro–B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007;115:3103-10
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54
   PubMed Web of Science ®Google Scholar
• Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-7
   PubMed Web of Science ®Google Scholar
• Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004;44:1328-33
   PubMed Web of Science ®Google Scholar
• Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994;343:440-44
   PubMed Web of Science ®Google Scholar
• Davidson NC, Struthers AD. Brain natriuretic peptide. J Hypertens 1994;12:329-36
   PubMed Web of Science ®Google Scholar
• McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure. N Engl J Med 1971;285:781-87
   Google Scholar
• Ho KKL, Pinsky JL, Kannel WB, et al. The epidemiology of congestive heart failure: the Framingham Study. J Am Coll Cardiol 1993;22(Suppl A):6A-13A
   PubMedGoogle Scholar
• Gillum RF. Epidemiology of heart failure in the United States. Am Heart J 1993;126:1042-47
   PubMed Web of Science ®Google Scholar
• MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66,547 patients hospitalized between 1986 and 1995. Circulation 2000;102:1126-31
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997;350:829-33
   PubMed Web of Science ®Google Scholar
• Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202
   PubMed Web of Science ®Google Scholar
• Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002;288:1252-9
   PubMed Web of Science ®Google Scholar
• SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA, et al. Effect of catopril on mortality in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1997;327:669-77
   Google Scholar
• Abraham WT. Beta-blockers: the new standard of therapy for mild heart failure. Arch Intern Med 2000;160:1237-47
   PubMed Web of Science ®Google Scholar
• Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology. The essentials. 2nd edition. Williams and Wilkins, Baltimore, MD; 1988
   Google Scholar
• McMurray JJV, Stewart S. The burden of heart failure. Eur Heart J Suppl 2002;4(Suppl D):D50-8
   Google Scholar
• Davies MK, Hobbs FDR, Davis RC, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England study: a population based study. Lancet 2001;358:439-44
   PubMed Web of Science ®Google Scholar
• Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population. The Rotterdam Study. Eur Heart J 1999;20:447-55
   PubMed Web of Science ®Google Scholar
• Ueda R, Yokouchi M, Suzuki T, et al. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med 2003;114:266-70
   PubMed Web of Science ®Google Scholar
• Ray P, Arthaud M, Lefort Y, Birolleau S, et al. Usefulness of B-type natriuretic peptide in elderly patients with acute dyspnea. Intensive Care Med 2004;30:2230-6
   PubMed Web of Science ®Google Scholar
• Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 2002;359:1430-2
   PubMed Web of Science ®Google Scholar
• Cosson S. Usefulness of B-type natriuretic peptide (BNP) as a screen for left ventricular abnormalities in diabetes mellitus. Diabetes Metab 2004;30:381-6
   PubMed Web of Science ®Google Scholar
• Magnusson M, Melander O, Israelsson B, et al. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004;27:1929-35
   PubMed Web of Science ®Google Scholar
• Epshteyn V, Morrison K, Krishnaswamy P, et al. Utility of B-type natriuretic peptide (BNP] as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003;26:2081-7
   PubMed Web of Science ®Google Scholar
• Baker DW, Bahler RC, Finkelhor RS, et al. Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure. Am Heart J 2003;146:736-40
   PubMed Web of Science ®Google Scholar
• Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of false positive screening mamograms and clinical breast examinations. N Engl J Med 1998;338:1089-96
   PubMed Web of Science ®Google Scholar
• Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365-71
   PubMed Web of Science ®Google Scholar
• Vanderheyden M, Goethals M, Verstreken S, et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 2004;44:2349-54
   PubMed Web of Science ®Google Scholar
• Daniels LB, Maisel A. B-type natriuretic peptide: time to incorporate natriuretic peptides in our practice. J Cardiovasc Med 2006;7:414-5
   Google Scholar
• Galasko GI, Lahiri A, Barnes SC, et al. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 2005;26:2269-76
   PubMed Web of Science ®Google Scholar
• Nakamura M, Endo H, Nasu M, et al. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002;87:131-5
   PubMed Web of Science ®Google Scholar
• Nielsen OW, McDonagh TA, Robb SD, et al. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003;41:113-20
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Gubens MA, Fonarow GC, et al. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004;43:1019-26
   PubMed Web of Science ®Google Scholar
• Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide (BNP) predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131-8
   PubMed Web of Science ®Google Scholar
• Baggish AL, van Kimmenade R, Bayes-Genis A, et al. Hemoglobin and N-terminal pro–brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure Results from the International Collaborative of NT-proBNP (ICON) Study. Clin Chim Acta 2007;381:145-50
   PubMed Web of Science ®Google Scholar
• Cheng VL, Krishnaswamy P, Kazanegra R, et al. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure. J Am Coll Cardiol 2001;37:386-91
   PubMed Web of Science ®Google Scholar
• Bettencourt P, Ferreira S. Azevedo A, et al. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcomes after hospital discharge in patients with heart failure. Am J Med 2002;113:215-9
   PubMed Web of Science ®Google Scholar
• Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110:2168-74
   PubMed Web of Science ®Google Scholar
• Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-83
   PubMed Web of Science ®Google Scholar
• Richards M, Nicholls MG, Espiner EA, et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006;47:52-60
   PubMed Web of Science ®Google Scholar
• Schnabel R, Lubos E, Rupprecht HJ, et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 2006;47:552-8
   PubMed Web of Science ®Google Scholar
• Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Gupta R, Na B, et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007;297:169-76
   PubMed Web of Science ®Google Scholar
• Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91
   PubMed Web of Science ®Google Scholar
• Talwar S, Squire IB, Downie PF, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction: correlation with left ventricular systolic dysfunction. Eur Heart J 2000;21:1514-21
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21
   PubMed Web of Science ®Google Scholar
• Lindahl B, Lindback J, Jernberg T, et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 2005;45:533-41
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264-72
   PubMed Web of Science ®Google Scholar
• De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-92
   PubMed Web of Science ®Google Scholar
• Westerhout CM, Fu Y, Lauer MS, et al. Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. J Am Coll Cardiol 2006;48:939-47
   PubMed Web of Science ®Google Scholar
• Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004;44:335-9
   PubMed Web of Science ®Google Scholar
• Kwan G, Isakson SR, Beede J, et al. Short-term serial sampling of natriuretic peptides in patients presenting with chest pain. J Am Coll Cardiol 2007;49:1186-92
   PubMed Web of Science ®Google Scholar
• James SK, Lindback J, Tilly J, et al. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol 2006;48:1146-54
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls MG, Yandle TG, et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart 1999;81:114-20
   PubMed Web of Science ®Google Scholar
• Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7
   PubMed Web of Science ®Google Scholar
• Tapanainen JM, Lindgren KS, Makikallio TH, et al. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2004;43:757-63
   PubMed Web of Science ®Google Scholar
• Watanabe J, Shiba N, Shinozaki T, et al. Prognostic value of plasma brain natriuretic peptide combined with left ventricular dimensions in predicting sudden death of patients with chronic heart failure. J Card Fail 2005;11:50-5
   PubMed Web of Science ®Google Scholar
• Verma A, Kilicaslan F, Martin DO, et al. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 2006;92:190-5
   PubMed Web of Science ®Google Scholar
• Klingenberg R, Zugck C, Becker R, et al. Raised B-type natriuretic peptide predicts implantable cardioverter-defibrillator therapy in patients with ischaemic cardiomyopathy. Heart 2006;92:1323-4
   PubMed Web of Science ®Google Scholar
• Lellouche N, De Diego C, Cesario DA, et al. Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy. Am J Cardiol 2007;99:242-6
   PubMed Web of Science ®Google Scholar
• Fruhwald FM, Fahrleitner-Pammer A, Berger R, et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 2007;28:1592-7
   PubMed Web of Science ®Google Scholar
• Sinha AM, Filzmaier K, Breithardt OA, et al. Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. Am J Cardiol 2003;91:755-8
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial [Val-HeFT]. Am Heart J 2005;149:548-57
   PubMed Web of Science ®Google Scholar
• Ray SG. Natriuretic peptides in heart valve disease. Heart 2006;92:1194-7
   PubMed Web of Science ®Google Scholar
• Sutton TM, Stewart RA, Gerber IL, et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 2003;41:2280-7
   PubMed Web of Science ®Google Scholar
• Brookes CI, Kemp MW, Hooper J, et al. Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. J Heart Valve Dis 1997;6:608-12
   PubMed Web of Science ®Google Scholar
• Yusoff R, Clayton N, Keevil B, et al. Utility of plasma N-terminal brain natriuretic peptide as a marker of functional capacity in patients with chronic severe mitral regurgitation. Am J Cardiol 2006;97:1498-501
   PubMed Web of Science ®Google Scholar
• Detaint D, Messika-Zeitoun D, Avierinos JF, et al. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 2005;111:2391-7
   PubMed Web of Science ®Google Scholar
• Nakamura M, Kawata Y, Yoshida H, et al. Relationship between plasma atrial and brain natriuretic peptide concentration and hemodynamic parameters during percutaneous transvenous mitral valvulotomy in patients with mitral stenosis. Am Heart J 1992;124:1283-8
   PubMed Web of Science ®Google Scholar
• Tharaux PL, Dussaule JC, Hubert-Brierre J, et al. Plasma atrial and brain natriuretic peptides in mitral stenosis treated by valvulotomy. Clin Sci 1994;87:671-7
   PubMed Web of Science ®Google Scholar
• Gerber IL, Stewart RA, Legget ME, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003;107:1884-90
   PubMed Web of Science ®Google Scholar
• Gerber IL, Legget ME, West TM, et al. Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol 2005;95:898-901
   PubMed Web of Science ®Google Scholar
• Lim P, Monin JL, Monchi M, et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J 2004;25:2048-53
   PubMed Web of Science ®Google Scholar
• Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004;109:2302-8
   PubMed Web of Science ®Google Scholar
• Ikeda T, Matsuda K, Itoh H, et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 1997;133:307-14
   PubMed Web of Science ®Google Scholar
• Nessmith MG, Fukuta H, Brucks S, et al. Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol 2005;96:1445-8
   PubMed Web of Science ®Google Scholar
• Ozkan M, Baysan O, Erinc K, et al. Brain natriuretic peptide and the severity of aortic regurgitation: is there any correlation? J Int Med Res 2005;33:454-9
   PubMed Web of Science ®Google Scholar
• Eimer MJ, Ekery DL, Rigolin VH, et al. Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation and preserved left ventricular systolic function. Am J Cardiol 2004;94:676-8
   PubMed Web of Science ®Google Scholar
• Gerber IL, Stewart RA, French JK, et al. Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation. Am J Cardiol 2003;92:755-8
   PubMed Web of Science ®Google Scholar
• Hutfless R, Kazanegra R, Madani M, et al. Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J Am Coll Cardiol 2004;43:1873-9
   PubMed Web of Science ®Google Scholar
• Wazni OM, Martin DO, Marrouche NF, et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2004;110:124-7
   PubMed Web of Science ®Google Scholar
• Feringa HH, Schouten O, Dunkelgrun M, et al. Plasma N-terminal pro-B-type natriuretic peptide as long-term prognostic marker after major vascular surgery. Heart 2007;93:226-31
   PubMed Web of Science ®Google Scholar
• McCullough PA, Sandberg KR. B-type natriuretic peptide and renal disease. Heart Fail Rev 2003;8:355-8
   PubMed Web of Science ®Google Scholar
• Munagala VK, Burnett JC Jr, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004;29:707-69
   PubMed Web of Science ®Google Scholar
• Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001;76:1111-9
   PubMed Web of Science ®Google Scholar
• DeFilippi CR, Fink JC, Nass CM, et al. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005;46:35-44
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Wada A, Sakai H, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2006;47:582-6
   PubMed Web of Science ®Google Scholar
• McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-9
   PubMed Web of Science ®Google Scholar
• Hall C. Essential biochemistry and physiology of (NT-pro) BNP. Eur J Heart Fail 2004;6:257-60
   PubMed Web of Science ®Google Scholar
• Pemberton CJ, Johnson ML, Yandle TG, et al. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000;36:355-9
   PubMed Web of Science ®Google Scholar
• Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006;47:91-7
   PubMed Web of Science ®Google Scholar
• Lamb EJ, Vickery S, Price CP. Amino-terminal pro-brain natriuretic peptide to diagnose congestive heart failure in patients with impaired kidney function. J Am Coll Cardiol 2006;48:1060-1
   PubMedGoogle Scholar
• Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345-53
   PubMed Web of Science ®Google Scholar
• Herrmann Z, Uhl W, Steinberg HW, Dworschack R. The influence of renal function on NT-proBNP levels in various disease groups. Clin Lab 2003;49:649-56
   PubMedGoogle Scholar
• Akiba T, Tachibana K, Togashi K, et al. Plasma human brain natriuretic peptide in chronic renal failure. Clin Nephrol 1995;44(Suppl 1):S61-64
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;2(Suppl 1):S46-75
   Google Scholar
• Haug C, Metzele A, Steffgen J, et al. Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure. Horm Metab Res 1994;26:246-9
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254-8
   PubMed Web of Science ®Google Scholar
• Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590-5
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600
   PubMed Web of Science ®Google Scholar
• Daniels LB, Clopton P, Bhalla V, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J 2006;151:1006-12
   PubMed Web of Science ®Google Scholar
• Sarzani R, Dessi-Fulgheri P, Paci VM, et al. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest 1996;19:581-5
   PubMed Web of Science ®Google Scholar
• Dessi-Fulgheri P, Sarzani R, Rappelli A. The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. J Nephrol 1998;11:296-9
   PubMed Web of Science ®Google Scholar
• Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006;47:85-90
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RRJ, et al. Effect of Body Mass Index on Diagnostic and Prognostic Usefulness of Amino-Terminal Pro–Brain Natriuretic Peptide in Patients With Acute Dyspnea. Arch Intern Med 2007;167:400-7
   PubMed Web of Science ®Google Scholar
• McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003;10:198-204
   PubMed Web of Science ®Google Scholar
• Mogelvang R, Goetze J, Schnohr P, et al. Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. J Am Coll Cardiol 2007;50:1694-701
   PubMed Web of Science ®Google Scholar
• Mitaka C, Hirata Y, Nagura T, et al. Increased plasma concentrations of brain natriuretic peptide in patients with acute lung injury. J Crit Care 1997;12:66-71
   PubMed Web of Science ®Google Scholar
• Maisel AS, DiSomma S. B-type natriuretic peptide-guided therapy and prognosis in acutely ill patients with pulmonary disease. Criti Care Med 2007;35:301-3
   PubMed Web of Science ®Google Scholar
• Berman B, Spragg R, Maisel A. B-type natriuretic peptide (BNP) levels in differentiating congestive heart failure from acute respiratory distress syndrome (ARDS). Abstracts from the 75th Annual Scientific Meeting of the American Heart Association. Circulation 2002;106:S3191
   Google Scholar
• Bal L, Thierry S, Brocas E, et al. B-type natriuretic peptide (BNP) and N-terminal-proBNP for heart failure diagnosis in shock or acute respiratory distress. Acta Anaesthesiol Scand 2006;50:340-7
   PubMed Web of Science ®Google Scholar
• Maeder M, Ammann P, Rickli H, et al. Elevation of B-type natriuretic peptide levels in acute respiratory distress syndrome. Swiss Med Wkly 2003;133:515-8
   PubMed Web of Science ®Google Scholar
• Bando M, Ishii Y, Sugiyama Y, et al. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999;93:507-14
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-8
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70
   PubMed Web of Science ®Google Scholar
• Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764-70
   PubMed Web of Science ®Google Scholar
• Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003;107:2545-7
   PubMed Web of Science ®Google Scholar
• Pruszczyk P, Kostrubiec M, Bochowicz A, et al. N-terminal pro–brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003;22:649-53
   PubMed Web of Science ®Google Scholar
• Kucher N, Printzen G, Doernhoefer T, et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003;107:1576-8
   PubMed Web of Science ®Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254-8
   PubMed Web of Science ®Google Scholar
• Maisel AS, Clopton P, Krishnaswamy P, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J 2004;147:1078-84
   PubMed Web of Science ®Google Scholar
• Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345-53
   PubMed Web of Science ®Google Scholar
• Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82
   PubMed Web of Science ®Google Scholar
• Kawai K, Hata K, Tanaka K, et al. Attenuation of biologic compensatory action of cardiac natriuretic peptide system with aging. Am J Cardiol 2004;93:719-23
   PubMed Web of Science ®Google Scholar
• Chang AY, Abdullah SM, Jain T, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol 2007;49:109-16
   PubMed Web of Science ®Google Scholar
• Rudiger A, Gasser S, Fischler M, et al. Comparable increase of B-type natriuretic peptide and aminoterminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006;34:2140-4
   PubMed Web of Science ®Google Scholar
• Jones AE, Kline JA. Elevated brain natriuretic peptide in septic patients without heart failure. Ann Emerg Med 2003;42:714-5
   PubMed Web of Science ®Google Scholar
• Tomaru Ki K, Arai M, Yokoyama T, et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002;34:649-59
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kanda T, Takahashi T, et al. Interleukin- 6-induced reciprocal expression of SERCA and natriuretic peptides mRNA in cultured rat ventricular myocytes. J Int Med Res 2004;32:57-61
   PubMed Web of Science ®Google Scholar
• Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004;36:505-13
   PubMed Web of Science ®Google Scholar
• Charpentier J, Luyt CE, Fulla Y, et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004;32:660-5
   PubMed Web of Science ®Google Scholar
• Yildiz R, Yildirim B, Karincaoglu M, et al. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients. J Gastroenterol Hepatol 2005;20:1115-20
   PubMed Web of Science ®Google Scholar
• Wong F, Siu S, Liu P, et al. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci 2001;101:621-8
   PubMed Web of Science ®Google Scholar
• Henriksen JH, Gotze JP, Fuglsang S, et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-7
   PubMed Web of Science ®Google Scholar
• Kohno M, Horio T, Yasunari K, et al. Stimulation of brain natriuretic peptide release from the heart by thyroid hormone. Metabolism 1993;42:1059-64
   PubMed Web of Science ®Google Scholar
• Schultz M, Faber J, Kistorp C, et al. N-terminal pro- B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol 2004;60:54-9
   PubMed Web of Science ®Google Scholar
• Jin H, Afonso L, Singh A, et al. Case report: recurrent heart failure with preserved ejection fraction but markedly elevated BNP in a 51-year-old female on hemodialysis with oversized AV fistula. Int J Cardiol 2006;110:429-30
   PubMed Web of Science ®Google Scholar
• Leya FS, Arab D, Joyal D, et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 2005;45:1900-2
   PubMed Web of Science ®Google Scholar
• Babuin L, Alegria JR, Oh JK, et al. Brain natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy. J Am Coll Cardiol 2006;47:1489-91
   PubMed Web of Science ®Google Scholar
• The RESOLVD Investigators. Effects of Metoprolol CR in Patients With Ischemic and Dilated Cardiomyopathy The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study. Circulation 2000;101:378
   PubMed Web of Science ®Google Scholar
• Stanek B, Frey B, Hulsmann M, et al. Prognostic evaluation of neurohumoral plasma levels before and during β-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001;38:436-42
   PubMed Web of Science ®Google Scholar
• Hara Y, Hamada M, Shigematsu Y, et al. Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. Jpn Circ J 2000;64:365-9
   PubMedGoogle Scholar
• Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001;7:21-9
   PubMed Web of Science ®Google Scholar
• Silver MA, Maisel A, Yancy CW, et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004;10:1-30
   Google Scholar
• Dokainish H, Zoghbi WA, Lakkis NM, et al. Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. J Am Coll Cardiol 2005;45:1223-6
   PubMed Web of Science ®Google Scholar
• Logeart D, Saudubray C, Beyne P, et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol 2002;40:1794-800
   PubMed Web of Science ®Google Scholar
• Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43:635-41
   PubMed Web of Science ®Google Scholar
• Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006;47:742-8
   PubMed Web of Science ®Google Scholar
• Nohria A, Givertz MM. B-type natriuretic peptide and the stressed heart. J Am Coll Cardiol 2006;47:749-51
   PubMed Web of Science ®Google Scholar
• Jourdain G, Jondeau F, Funck P, et al. Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure The STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49:1733-9
   PubMed Web of Science ®Google Scholar
• Hawkridge AM, Heublein DM, Bergen HR, et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci 2005;102:17442-7
   PubMed Web of Science ®Google Scholar
• Maisel AS. The diagnosis of acute congestive heart failure: role of BNP measurements. Heart Fail Rev 2003;8:327-34
   PubMed Web of Science ®Google Scholar
• Morrison KL, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide (BNP) assay in differentiating CHF from lung disease in patients presenting with dyspnea. JACC 2002;39:202-9
   Google Scholar